This article is more than 5 years old. Information may no longer be current.
NxStage names Allan Collins as CMO
Click Here to Manage Email Alerts
Dialysis product manufacturer NxStage Medical Inc. has named Allan Collins, MD, FACP chief medical officer.
In this new role, Collins will lead a new medical affairs team in addition to continuing his current role as chair of the company's scientific advisory board, a position he has held since 2014.
"I'm excited to continue integrating medical insights with a robust dataset to engage key opinion leaders and expand patient access to NxStage's life-changing therapies," said Collins. "I look forward to collaborating with all the teams at NxStage to bring its innovative solutions to more patients."
Collins is a professor of medicine at the University of Minnesota. He is the director of the Chronic Research Disease Group, an interdisciplinary biomedical research group committed to the investigation of chronic illnesses to improve public health, and as part of this, served as the coordinating center for the United States Renal Data System (USRDS) and its Annual Data Report from 2000 through 2014.
Collins was presented the Distinguished Service Award by the National Kidney Foundation (NKF) in 2003, and served as the President of the NKF from 2006 through 2008. In 2014, Collins received the ASN Belding Scribner Award and the American Association of Kidney Patients Medal of Excellence Award.